** Shares of drug developer Seres Therapeutics MCRB.O rise 14.1% to 93 cents premarket
** Says the U.S. FDA has granted "Breakthrough Therapy" designation to its experimental treatment, SER-155
** The treatment helps reduce bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant to treat various types of blood cancers
** The transplant uses blood stem cells from a donor to replace bone marrow that's not producing enough healthy blood cells
** SER-155 was well-tolerated with no treatment-related serious adverse events in an early-stage study - MCRB
** The FDA's tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need
** Co is actively seeking a partner to provide financial resources and other capabilities to support its goal to maximize the SER-155 program opportunity
** Up to last close, stock down 41.2% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。